A new drug compared to chemo for advanced neuroendocrine carcinoma
Treatments studied
Part of Cancer clinical trials.
This study tests a new investigational drug called ZG006 against the chemotherapy your doctor would normally choose for advanced neuroendocrine carcinoma. The trial aims to see if ZG006 works better than standard chemotherapy for people whose cancer has progressed after earlier treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You have advanced neuroendocrine carcinoma (a cancer that starts in cells that make hormones)
- Your cancer is not small cell lung cancer or combined small cell lung cancer
- You have already tried at least one prior cancer treatment (like chemotherapy)
- Your cancer tests positive for DLL3 (a protein found on some cancer cells)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, ZG006, that targets a protein called DLL3 found on some cancer cells. It may be an option for people with small cell lung cancer or neuroendocrine carcinoma who have run out of standard treatments.
This trial is testing a new drug called ZG006 for people with advanced small cell lung cancer or neuroendocrine carcinoma. The study has two parts: first finding the right dose, then testing it in more people with neuroendocrine carcinoma.
This trial tests two new drugs, ZG006 and ZG005, for people with advanced small cell lung cancer or neuroendocrine carcinoma. The goal is to see if these drugs can shrink tumors or slow cancer growth.
This Phase 2 study tests a chemotherapy approach in people with metastatic grade 3 (high-grade) neuroendocrine cancer or a related rare mixed tumor. It may help shrink tumors and control disease when standard first treatments have not yet been given.
This trial tests a combination of two targeted therapies (surufatinib and serplulimab) plus standard chemotherapy (platinum and etoposide) for people with a rare, aggressive type of cancer called neuroendocrine carcinoma that started outside the lung. The goal is to see if this new combination works better than chemotherapy alone.
This trial tests whether adding a new drug, ZG005, to standard chemotherapy (etoposide and cisplatin) is better than the chemotherapy alone for treating advanced neuroendocrine carcinoma that has not been treated before. The study aims to see if the combination can help people live longer or slow the cancer's growth.
Hear when a new Neuroendocrine Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.